Cytek Biosciences Reports First Quarter 2025 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- JetBlue shares drop on creditor restructuring news amid bankruptcy filing fears
- Celestica (CLS) Tops Q3 EPS by 31c, Offers Guidance
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- CAE agrees to sell Flightscape unit to SITA for $500 million
Cytek Biosciences, Inc. (CTKB) Misses Q1 EPS by 7c, Misses on Revenue; Offers FY25 Revenue Guidance
May 8, 2025 4:36 PM EDTCytek Biosciences, Inc. (NASDAQ: CTKB) reported Q1 EPS of ($0.09), $0.07 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $41.5 million versus the consensus estimate of $43.82 million.
GUIDANCE:
Cytek Biosciences, Inc. sees FY2025 revenue of $196-210 million, versus the... More



